{"product_id":"management-of-acute-coronary-syndromes-9780470725573","title":"Management of Acute Coronary Syndromes","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eDesigned to provide busy clinicians with a comprehensive guide to the investigation, diagnosis, and treatment of Acute Coronary Syndrome (ACS), this book encompasses the latest technologies, including the use of biomarkers and non-invasive imaging procedures.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eList of contributors xiii\u003c\/p\u003e \u003cp\u003eForeword xv\u003cbr\u003e \u003ci\u003eEugene Braunwald\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 1 Pathophysiology of acute coronary syndromes 1\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eAlisa B. Rosen and Eli V. Gelfand\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 1\u003c\/p\u003e \u003cp\u003eFormation of atherosclerotic plaque 2\u003c\/p\u003e \u003cp\u003ePlaque instability and the development of ACS 5\u003c\/p\u003e \u003cp\u003eMyocardial ischemia 7\u003c\/p\u003e \u003cp\u003eThrombus formation 7\u003c\/p\u003e \u003cp\u003ePlatelets 7\u003c\/p\u003e \u003cp\u003eSecondary hemostasis 9\u003c\/p\u003e \u003cp\u003eDynamic obstruction 10\u003c\/p\u003e \u003cp\u003eProgressive mechanical obstruction 10\u003c\/p\u003e \u003cp\u003eInflammation 11\u003c\/p\u003e \u003cp\u003eSecondary unstable angina 11\u003c\/p\u003e \u003cp\u003eReferences 11\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 2 Diagnosis of acute coronary syndrome 13\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eEli V. Gelfand and Alisa B. Rosen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 13\u003c\/p\u003e \u003cp\u003eDefinition of myocardial infarction 13\u003c\/p\u003e \u003cp\u003eHistory 14\u003c\/p\u003e \u003cp\u003eRisk factors 17\u003c\/p\u003e \u003cp\u003ePhysical examination 17\u003c\/p\u003e \u003cp\u003eElectrocardiography 19\u003c\/p\u003e \u003cp\u003eThe pathophysiologic basis of ST segment\u003c\/p\u003e \u003cp\u003echanges during ischemia 19\u003c\/p\u003e \u003cp\u003eElectrocardiography in ST-elevation MI and identification of the infarct-related artery 20\u003c\/p\u003e \u003cp\u003eElectrocardiography in unstable angina and NSTEMI 26\u003c\/p\u003e \u003cp\u003eCardiac biomarkers 26\u003c\/p\u003e \u003cp\u003eNoninvasive imaging 29\u003c\/p\u003e \u003cp\u003eEchocardiography 29\u003c\/p\u003e \u003cp\u003eMyocardial perfusion imaging 30\u003c\/p\u003e \u003cp\u003eCoronary computed tomography 30\u003c\/p\u003e \u003cp\u003eCardiovascular magnetic resonance imaging 31\u003c\/p\u003e \u003cp\u003eStress testing for diagnosis of ACS 32\u003c\/p\u003e \u003cp\u003eOverall diagnostic pathway for ACS 32\u003c\/p\u003e \u003cp\u003eReferences 34\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 3 Unstable angina and non-ST-elevation myocardial infarction 37\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eEli V. Gelfand and Christopher P. Cannon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 37\u003c\/p\u003e \u003cp\u003eCauses of UA\/NSTEMI 37\u003c\/p\u003e \u003cp\u003ePresentation of UA\/NSTEMI 38\u003c\/p\u003e \u003cp\u003eGeneral strategies in management of UA\/NSTEMI 39\u003c\/p\u003e \u003cp\u003eRisk stratification of patients with UA\/NSTEMI 40\u003c\/p\u003e \u003cp\u003eInitial management of UA\/NSTEMI in the emergency department 42\u003c\/p\u003e \u003cp\u003ePharmacologic treatment of ischemia in UA\/NSTEMI 43\u003c\/p\u003e \u003cp\u003eBeta-blockers 44\u003c\/p\u003e \u003cp\u003eNitrates 44\u003c\/p\u003e \u003cp\u003eCalcium channel blockers 45\u003c\/p\u003e \u003cp\u003eAngiotensin-converting enzyme inhibitors 45\u003c\/p\u003e \u003cp\u003eMorphine 46\u003c\/p\u003e \u003cp\u003eOxygen 46\u003c\/p\u003e \u003cp\u003eInvasive versus conservative strategy 46\u003c\/p\u003e \u003cp\u003eAntiplatelet therapy in UA\/NSTEMI 49\u003c\/p\u003e \u003cp\u003eAspirin 54\u003c\/p\u003e \u003cp\u003eClopidogrel 55\u003c\/p\u003e \u003cp\u003ePrasugrel 57\u003c\/p\u003e \u003cp\u003eGlycoprotein IIb\/IIIa inhibitors 58\u003c\/p\u003e \u003cp\u003eAnticoagulant therapy in UA\/NSTEMI 61\u003c\/p\u003e \u003cp\u003eUnfractionated heparin 61\u003c\/p\u003e \u003cp\u003eEnoxaparin 62\u003c\/p\u003e \u003cp\u003eDirect thrombin inhibitors 65\u003c\/p\u003e \u003cp\u003eFondaparinux 66\u003c\/p\u003e \u003cp\u003eOral anticoagulation in UA\/NSTEMI 67\u003c\/p\u003e \u003cp\u003eFibrinolysis in UA\/NSTEMI 68\u003c\/p\u003e \u003cp\u003eEarly lipid-lowering therapy in patients with UA\/NSTEMI 68\u003c\/p\u003e \u003cp\u003ePredischarge noninvasive risk stratification after UA\/NSTEMI 69\u003c\/p\u003e \u003cp\u003eOverall management of UA\/NSTEMI 71\u003c\/p\u003e \u003cp\u003eReferences 71\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 4 ST-segment-elevation myocardial infarction 79\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eEli V. Gelfand and Christopher P. Cannon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 79\u003c\/p\u003e \u003cp\u003eGlobal treatment goals in STEMI 79\u003c\/p\u003e \u003cp\u003ePrehospital management and triage 80\u003c\/p\u003e \u003cp\u003eTransport decisions 82\u003c\/p\u003e \u003cp\u003eManagement prior to reperfusion 82\u003c\/p\u003e \u003cp\u003ePrimary reperfusion therapy for STEMI 83\u003c\/p\u003e \u003cp\u003eFibrinolysis 83\u003c\/p\u003e \u003cp\u003eCombination fibrinolysis 86\u003c\/p\u003e \u003cp\u003eMarkers of fibrinolysis effectiveness 86\u003c\/p\u003e \u003cp\u003eComplications of fibrinolysis 88\u003c\/p\u003e \u003cp\u003ePrimary percutaneous coronary intervention 88\u003c\/p\u003e \u003cp\u003eComparison of PCI with fibrinolysis 90\u003c\/p\u003e \u003cp\u003eTiming of primary PCI 91\u003c\/p\u003e \u003cp\u003ePCI following fibrinolytic therapy 94\u003c\/p\u003e \u003cp\u003eRescue PCI 94\u003c\/p\u003e \u003cp\u003eFacilitated PCI 94\u003c\/p\u003e \u003cp\u003eRoutine PCI after successful fibrinolysis 96\u003c\/p\u003e \u003cp\u003eOverall reperfusion strategy 97\u003c\/p\u003e \u003cp\u003eCoronary artery bypass grafting for treatment of STEMI 98\u003c\/p\u003e \u003cp\u003eAdjunctive pharmacologic treatment of STEMI 98\u003c\/p\u003e \u003cp\u003eAntiplatelet agents 98\u003c\/p\u003e \u003cp\u003eAnticoagulation therapy 101\u003c\/p\u003e \u003cp\u003eOther adjunctive therapy 105\u003c\/p\u003e \u003cp\u003eHospital care following successful reperfusion 110\u003c\/p\u003e \u003cp\u003eReferences 114\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 5 Special considerations in acute coronary syndromes 123\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJason Ryan and Eli V. Gelfand\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eSecondary unstable angina 123\u003c\/p\u003e \u003cp\u003eAcute coronary syndrome in patients with diabetes mellitus 123\u003c\/p\u003e \u003cp\u003eGeneral considerations 123\u003c\/p\u003e \u003cp\u003ePrimary ACS therapy in diabetics 124\u003c\/p\u003e \u003cp\u003eGlycemic control in diabetics with ACS 125\u003c\/p\u003e \u003cp\u003eCoronary revascularization in diabetics 126\u003c\/p\u003e \u003cp\u003eMetabolic syndrome and ACS 127\u003c\/p\u003e \u003cp\u003eChronic kidney disease in ACS 127\u003c\/p\u003e \u003cp\u003eYoung patients with ACS 130\u003c\/p\u003e \u003cp\u003eACS in the setting of cocaine use 130\u003c\/p\u003e \u003cp\u003eACS in patients with normal coronary arteries or mild CAD 132\u003c\/p\u003e \u003cp\u003eMyocarditis 132\u003c\/p\u003e \u003cp\u003eAcute transient apical ballooning syndrome 133\u003c\/p\u003e \u003cp\u003ePostoperative ACS 134\u003c\/p\u003e \u003cp\u003eACS in a pregnant woman 135\u003c\/p\u003e \u003cp\u003eHyperthyroidism and ACS 136\u003c\/p\u003e \u003cp\u003eACS in patients exposed to radiation 137\u003c\/p\u003e \u003cp\u003eTrauma and ACS 137\u003c\/p\u003e \u003cp\u003eReferences 137\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 6 Complications of acute coronary syndrome 141\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJan M. Pattanayak and Eli V. Gelfand\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 141\u003c\/p\u003e \u003cp\u003ePump failure 141\u003c\/p\u003e \u003cp\u003eGeneral principle 141\u003c\/p\u003e \u003cp\u003eClinical presentation 142\u003c\/p\u003e \u003cp\u003ePrognosis 144\u003c\/p\u003e \u003cp\u003eTreatment 144\u003c\/p\u003e \u003cp\u003eRight ventricular infarction 148\u003c\/p\u003e \u003cp\u003eIntroduction 148\u003c\/p\u003e \u003cp\u003eClinical presentation 148\u003c\/p\u003e \u003cp\u003eDiagnosis 149\u003c\/p\u003e \u003cp\u003eManagement 150\u003c\/p\u003e \u003cp\u003ePrognosis 152\u003c\/p\u003e \u003cp\u003eMechanical complications of ACS 152\u003c\/p\u003e \u003cp\u003eIntroduction 152\u003c\/p\u003e \u003cp\u003eLeft ventricular free wall rupture 152\u003c\/p\u003e \u003cp\u003eVentricular septal rupture 153\u003c\/p\u003e \u003cp\u003eAcute mitral regurgitation 154\u003c\/p\u003e \u003cp\u003eLeft ventricular aneurysm 155\u003c\/p\u003e \u003cp\u003eLeft ventricular pseudoaneurysm 157\u003c\/p\u003e \u003cp\u003ePericardial complications 157\u003c\/p\u003e \u003cp\u003eArrhythmic complications of ACS 159\u003c\/p\u003e \u003cp\u003eBradyarrhythmias 159\u003c\/p\u003e \u003cp\u003eAtrial fibrillation 163\u003c\/p\u003e \u003cp\u003eVentricular tachycardia and fibrillation 163\u003c\/p\u003e \u003cp\u003eComplications involving bleeding 164\u003c\/p\u003e \u003cp\u003eComplications of percutaneous coronary intervention 165\u003c\/p\u003e \u003cp\u003eReferences 170\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 7 Post-hospitalization care of patients with acute coronary syndrome 173\u003c\/b\u003e\u003cbr\u003e \u003ci\u003eJersey Chen and Eli V. Gelfand\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 173\u003c\/p\u003e \u003cp\u003ePharmacologic measures 173\u003c\/p\u003e \u003cp\u003eAspirin 173\u003c\/p\u003e \u003cp\u003eClopidogrel 174\u003c\/p\u003e \u003cp\u003eBeta adrenergic blockade 177\u003c\/p\u003e \u003cp\u003eRenin–angiotensin–aldosterone inhibitors 179\u003c\/p\u003e \u003cp\u003eLipid-lowering therapy 185\u003c\/p\u003e \u003cp\u003eWarfarin 189\u003c\/p\u003e \u003cp\u003eInfluenza vaccination 192\u003c\/p\u003e \u003cp\u003eMedications of limited benefit to patients following ACS 192\u003c\/p\u003e \u003cp\u003eVitamins\/antioxidants 192\u003c\/p\u003e \u003cp\u003eEstrogen replacement therapy 192\u003c\/p\u003e \u003cp\u003eNonsteroidal anti-inflammatory agents and related compounds 194\u003c\/p\u003e \u003cp\u003eNonpharmacologic measures 195\u003c\/p\u003e \u003cp\u003eAntiarrhythmic devices 195\u003c\/p\u003e \u003cp\u003eTherapy of comorbidities following ACS 198\u003c\/p\u003e \u003cp\u003eDiabetes mellitus 198\u003c\/p\u003e \u003cp\u003eHypertension 199\u003c\/p\u003e \u003cp\u003eDepression 199\u003c\/p\u003e \u003cp\u003eLifestyle recommendations following ACS 200\u003c\/p\u003e \u003cp\u003eGeneral physical activity and structured cardiac rehabilitation 200\u003c\/p\u003e \u003cp\u003eSexual activity after ACS 201\u003c\/p\u003e \u003cp\u003eSmoking cessation 201\u003c\/p\u003e \u003cp\u003eDiet\/nutrition and weight loss 202\u003c\/p\u003e \u003cp\u003eReferences 204\u003c\/p\u003e \u003cp\u003eAppendix 209\u003c\/p\u003e \u003cp\u003eIndex 217\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49402419544407,"sku":"9780470725573","price":77.36,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470725573.jpg?v=1730480343","url":"https:\/\/bookcurl.com\/products\/management-of-acute-coronary-syndromes-9780470725573","provider":"Book Curl","version":"1.0","type":"link"}